Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05874921 · ClinicalTrials.gov registry record
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
A clinical trial of Urothelial Carcinoma and Carcinoma, Transitional Cell, sponsored by UroGen Pharma.
- Recruiting
- Registry status
- 400
- Enrollment target
- 20
- Study locations
NCT05874921: Recruiting study of Urothelial Carcinoma and Carcinoma, Transitional Cell, sponsored by UroGen Pharma.
NCT05874921 is a study of Urothelial Carcinoma and Carcinoma, Transitional Cell that is actively recruiting participants, run by UroGen Pharma. The registered enrollment target is 400 participants, above the 234-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (71% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05874921, a study of Urothelial Carcinoma and Carcinoma, Transitional Cell, is actively recruiting participants, sponsored by UroGen Pharma.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.
Conditions Studied
Interventions
- DRUG Jelmyto (mitomycin) for pyelocalyceal solution
Study Locations (20)
Florida
- University of Florida - Gainesville
- Mount Sinai Medical Center of Florida, Inc. - Miami
- H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. - Tampa
New York
- The Feinstein Institutes for Medical Research - Lake Success
- NYU Grossman School of Medicine - New York
- SUNY Upstate - Syracuse
Maryland
- Chesapeake Urology - Baltimore
- Johns Hopkins Medical Center - Baltimore
Massachusetts
- Mass General Hospital (MGH) - Boston
- The Brigham and Womens Hospital - Boston
California
- Providence St. Johns Health Center - Santa Monica
Illinois
- Northwestern University - Chicago
Indiana
- Indiana University - Indianapolis
Iowa
- The State University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2023-11-17 |
| Est. Completion | 2028-01 |
What NCT05874921 shows while recruiting
NCT05874921 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 234-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (71% higher).
The record links to 8 conditions, with Urothelial Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Jelmyto (mitomycin) for pyelocalyceal solution is the first listed.
NCT05874921 names 20 study sites across 14 states, led by Florida, New York, Maryland.
Frequently Asked Questions
What is clinical trial NCT05874921 about?
NCT05874921 is a clinical study titled "uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto". The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.
What is the current status of trial NCT05874921?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2023-11-17. Estimated completion is 2028-01.
What conditions does trial NCT05874921 study?
This clinical trial studies the following conditions: Urothelial Carcinoma, Carcinoma, Transitional Cell, Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter.
What interventions are being tested in trial NCT05874921?
The interventions under investigation include: Jelmyto (mitomycin) for pyelocalyceal solution (DRUG).
Who is sponsoring clinical trial NCT05874921?
This trial is sponsored by UroGen Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05874921 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Indiana, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05874921's enrollment target sits among peer trials
400 14th of 85 higher than 72 of 85 other Urothelial Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Urothelial Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria
RECRUITING
-
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
RECRUITING · Phase 3
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
RECRUITING · Phase 2
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI